



NEPHROLOGY GROUP

 **Publications: 24**

 **Impact Factor: 75.981**

 **Q1: 10**

PUBLICATIONS

- Arrieta-Lezama J, Selgas-Gutiérrez R. Comment on “Cost analysis and sociocultural profile of kidney patients. Impact of the treatment method”. *Nefrología*. 2015;35(1):115-6. Letter. IF: 1.207; Q4.
- Atilano-Carsi X, Bajo MA, del Peso G, Sánchez R, Selgas R. Normal values of bioimpedance vector in Spanish population. *Nutr Hosp*. 2015;31(3):1336-44. Article. IF: 1.497; Q3.
- Atilano-Carsi X, Miguel JL, Ara JM, Villanueva RS, García EG, Gutiérrez RS. Bioimpedance vector analysis as a tool for the determination and adjustment of dry weight in patients undergoing hemodialysis. *Nutr Hosp*. 2015;31(5):2220-9. Article. IF: 0.497; Q3.
- Bozic M, Álvarez A, de Pablo C, Sánchez-Niño MD, Ortiz A, Dolcet X, Encinas M, Fernández E, Valdivielso JM. Impaired Vitamin D signaling in endothelial cell leads to an enhanced leukocyte-endothelium interplay: implications for atherosclerosis development. *Plos One*. 2015;10(8):e0136863. Article. IF: 3.057; Q1.
- Elewa U, Fernández-Fernández B, Alegre R, Sánchez-Niño MD, Mahillo-Fernández I, Pérez-Gómez MV, El-Fishawy H, Belal D, Ortiz A. Modifiable risk factors for increased arterial stiffness in outpatient Nephrology. *Plos One*. 2015;10(4):e0123903. Article. IF: 3.057; Q1.
- Fernández-Ruiz M, Corrales I, Arias M, Campistol JM, Giménez E, Crespo J, López-Oliva MO, Beneyto I, Martín-Moreno PL, Llamas-Fuente F, Gutiérrez A, García-Álvarez T, Guerra-Rodríguez R, Calvo N, Fernández-Rodríguez A, Taberero-Romo JM, Navarro MD, Ramos-Verde A, Aguado JM, Navarro D. Association between individual and combined snps in genes related to innate immunity and incidence of CMV infection in seropositive kidney transplant recipients. *Am J Transplant*. 2015;15(5):1323-35. Article. IF: 5.669; D1.
- González E, Bajo MA, Carrero JJ, Lindholm B, Grande C, Sánchez-Villanueva R, del Peso G, Díaz-Almirón M, Iglesias P, Díez JJ, Selgas R. An increase of plasma advanced oxidation protein products levels is associated with cardiovascular risk in incident peritoneal dialysis patients: A pilot study. *Oxid Med Cell Longev*. 2015;219569. Article. IF: 4.492; Q2.
- González-Mateo GT, Aguirre AR, Loureiro J, Abensur H, Sandoval P, Sánchez-Tomero JA, del Peso G, Jiménez-Heffernan JA, Ruiz-Carpio V, Selgas R, López-Cabrera M, Aguilera A, Liappas G. rapamycin protects from type-i peritoneal membrane failure inhibiting the angiogenesis, lymphangiogenesis, and Endo-MT. *Biomed Res Int*. 2015;989560. Article. IF: 2.134; Q3.
- Janeiro D, Portoles J, Tato AM, López-Sánchez P, del Peso G, Rivera M, Castellano I, Fernández-Reyes MJ, Pérez-Gómez V, Ortega M, Martínez-Miguel P, Felipe C, Caparrós G, Ortiz A, Selgas R. Peritoneal dialysis can be an option for dominant polycystic kidney disease: an observational study. *Periton Dialysis Int*. 2015;35(5):530-6. Article. IF: 1.298; Q3.
- Liappas G, González-Mateo GT, Majano P, Sánchez-Tomero JA, Ruiz-Ortega M, Díez RR, Martín P, Sánchez-Díaz R, Selgas R, López-Cabrera M, Peralta AA. T helper 17/regulatory t cell balance and experimental models of peritoneal dialysis-induced damage. *Biomed Res Int*. 2015;416480. Review. IF: 2.134; Q3.
- Martínez-Miguel P, de Sequera P, Albalade M, Medrano D, Sánchez-Villanueva R, Molina A, Sousa F, Benito J, Núñez J, Vozmediano C, Aragoncillo I, Barril G, Rodríguez-Puyol D, Pérez-García R, López-Ongil S. Evaluation of a polynephron dialysis membrane considering new aspects of biocompatibility. *Int J Artif Organs*. 2015;38(1):45-53. Article. IF: 1.005; Q3.



- Nozal P, Garrido S, Martínez-Ara J, Picazo ML, Yébenes L, Álvarez-Doforno R, Pinto S, de Córdoba SR, López-Trascasa M. Case report: lupus nephritis with autoantibodies to complement alternative pathway proteins and C3 gene mutation. *BMC Nephrol.* 2015;16:40. Article. IF: 2.289; Q2.
- Ortiz A, Sánchez-Niño MD. Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy was underpowered. *Drug Des Dev Ther.* 2015;9:5873-4. Letter. IF: 2.881; Q2.
- Ortiz A, Sánchez-Niño MD, Izquierdo MC, Martín-Cleary C, García-Bermejo L, Moreno JA, Ruíz-Ortega M, Draibe J, Cruzado JM, García-González MA, López-Novoa JM, Soler MJ, Sanz AB. Translational value of animal models of kidney failure. *Eur J Pharmacol.* 2015;759:205-20. Article. IF: 2.73; Q2.
- Pérez-Gómez MV, Sánchez-Niño MD, Sanz AB, Martín-Cleary C, Ruíz-Ortega M, Egado J, Navarro-González JF, Ortiz A, Fernández-Fernández B. Horizon 2020 in Diabetic Kidney Disease: The clinical trial pipeline for add-on therapies on top of renin angiotensin system blockade. *J Clin Med.* 2015;4(6):1325-47. Review. Not indexed.
- Rabasco C, Cavero T, Román E, Rojas-Rivera J, Olea T, Espinosa M, Cabello V, Fernández-Juarez G, González F, Ávila A, Baltar JM, Díaz M, Alegre R, Elías S, Antón M, Frutos MA, Pobes A, Blasco M, Martín F, Bernis C, Macías M, Barroso S, de Lorenzo A, Ariceta G, López-Mendoza M, Rivas B, López-Revuelta K, Campistol JM, Mendizabal S, de Córdoba SR, Praga M. Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. *Kidney Int.* 2015;88(5):1153-60. Article. IF: 7.683; D1.
- Ramos AM, González-Guerrero C, Sanz A, Sánchez-Niño MD, Rodríguez-Osorio L, Martín-Cleary C, Fernández-Fernández B, Ruíz-Ortega M, Ortiz A. Designing drugs that combat kidney damage. *Expert Opin Drug Dis.* 2015;10(5):541-56. Review. IF: 3.484; Q1.
- Rodríguez-Díez R, Rayego-Mateos S, Orejudo M, Aroeira LS, Selgas R, Ortiz A, Egado J, Ruíz-Ortega M. TGF- β Blockade increases renal inflammation caused by the C-terminal module of the CCN2. *Mediat Inflamm.* 2015;506041. Article. IF: 3.418; Q2.
- Rodríguez-Sanz A, Sánchez-Alonso P, Bellón T, Alajarin R, Martínez-Cabeza V, Selgas R, Vaquero JJ, Álvarez-Builla J. Synthesis and biological evaluation of pyridazino[1',6':1,2]pyrido[3,4-b]indolinium and pyridazino [1,6-a] benzimidazolium salts as anti-inflammatory agents. *Eur J Med Chem.* 2015;93:83-92. Article. IF: 3.902; Q1.
- Sánchez-Niño MD, Carpio D, Sanz AB, Ruíz-Ortega M, Mezzano S, Ortiz A. Lyso-Gb3 activates Notch1 in human podocytes. *Hum Mol Genet.* 2015;24(20):5720-32. Article. IF: 5.985; D1.
- Sánchez-Niño MD, Fernández-Fernández B, Pérez-Gómez MV, Poveda J, Sanz AB, Cannata-Ortiz P, Ruíz-Ortega M, Egado J, Selgas R, Ortiz A. Albumin-induced apoptosis of tubular cells is modulated by BASP1. *Cell Death Dis.* 2015;6:e1644. Article. IF: 5.378; Q1.
- Sánchez-Niño MD, Ortiz A. 'That Obscure Object of Desire': in systemic lupus erythematosus B-cell activating factor/B-lymphocyte stimulator is targeted both by the immune system and by physicians. *Nephrol Dial Transpl.* 2015;30(3):394-400. Review. IF: 4.085; Q1.
- Santamaría B, Ucero AC, Benito-Martín A, Vicent MJ, Orzáez M, Celdrán A, Selgas R, Ruíz-Ortega M, Ortiz A. Biocompatibility reduces inflammation-induced apoptosis in mesothelial cells exposed to peritoneal dialysis fluid. *Blood Purificat.* 2015;39(42430):200-9. Article. IF: 1.404; Q3.
- Valino-Rivas L, Baeza-Bermejillo C, González-Lafuente L, Sanz AB, Ortiz A, Sánchez-Niño MD. CD74 in kidney disease. *Front Immunol.* 2015;6:483. Article. IF: 5.695; Q1.